Arcutis biotherapeutics stock.

Sep 29, 2022 · Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. Arcutis Biotherapeutics' shares are down 15% year to date. Read more to ...

Arcutis biotherapeutics stock. Things To Know About Arcutis biotherapeutics stock.

These 6 analysts have an average price target of $34.83 versus the current price of Arcutis Biotherapeutics at $3.3701, implying upside. Below is a summary of how these 6 analysts rated Arcutis ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique ...Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Satsuma Pharmaceuticals, and Ocugen. According to TipRanks , Ear has an average return of 18.8% and a 25.00% ...Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45.

What this means: InvestorsObserver gives Arcutis Biotherapeutics Inc (ARQT) an overall rank of 33, which is below average. Arcutis Biotherapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.

The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The simple moving average for the last 20 days is …

Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.These 6 analysts have an average price target of $34.83 versus the current price of Arcutis Biotherapeutics at $3.3701, implying upside. Below is a summary of how these 6 analysts rated Arcutis ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated ...Nov 27, 2023 · The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The […] In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. Morgan Stanley, Cowen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, …

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common …

Nov 29, 2023 · The Arcutis Biotherapeutics Inc stock price fell by -0.529% on the last day (Wednesday, 22nd Nov 2023) from $1.89 to $1.88. During the last trading day the stock fluctuated 17.51% from a day low at $1.77 to a day high of $2.08. The price has fallen in 6 of the last 10 days and is down by -14.55% for this period. Earlier this month, the company added to its pipeline assets by acquiring privately held Ducentis Biotherapeutics for an upfront cash payment of ~$16 million and Arcutis stock valued at ~$14 ...--Arcutis Biotherapeutics, Inc., ... today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 106,500 ...Sep 7, 2023 · Shares of Arcutis Biotherapeutics ... The healthcare company's stock closed last week at $8.96 a share and fell to as low as $7.47 on Thursday after Arcutis reported trial data regarding a ... In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics ( ARQT – Research Report ), with a price target of $57.00. The company’s shares ...

Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($3.78) to ($2.65) per share. Arcutis Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.Aug 8, 2023 · Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.22. After the upgrade, the seven analysts covering Arcutis Biotherapeutics are now predicting revenues of US$44m in 2023. If met, this would reflect a substantial 294% improvement in sales compared to ...The high in the last 52 weeks of Arcutis Biotherapeutics stock was 18.04. According to the current price, Arcutis Biotherapeutics is 11.03% away from the 52 …Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $44.00. The associated price target is ...There’s also Arcutis Biotherapeutics (NASDAQ:ARQT), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face FDA decision on Dec. 16.

Health Technology. Industry. Pharmaceuticals: Major. No executives to display. Corporate headquarters. --, --. Find real-time ARQT - Arcutis Biotherapeutics Inc stock quotes, company profile, news ... In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and ...

Phone Number 805-418-5006. Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for …Best Stocks & ETFs. Best Penny Stocks. Best S&P 500 ETFs. Best Swing Trade Stocks. ... Arcutis Biotherapeutics ARQT is set to give its latest quarterly earnings report on Tuesday, 2023-02-28. Here ...Recent developments: Arcutis Biotherapeutics' stock rose 15% in early June after prescription data showed a 40% increase in Q1 for their psoriasis cream, Zoryve. Q1 2023 Earnings.Nov 29, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ... Company profile page for Arcutis Biotherapeutics Inc including stock price, company news, executives, board members, and contact informationArcutis Biotherapeutics, Inc. (Nasdaq: ARQT). Biotechnology Research. Westlake Village, California 16,359 followers. Bioscience, applied to the skin.Arcutis Biotherapeutics (ARQT) In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $57.00. The company’s ...Review which funds and institutions currently hold Arcutis Biotherapeutics Inc Ordinary Shares (ARQT:XNAS) stock for ownership information.The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by …Shares of Arcutis Biotherapeutics ... The healthcare company's stock closed last week at $8.96 a share and fell to as low as $7.47 on Thursday after Arcutis reported trial data regarding a ...

Do the numbers hold clues to what lies ahead for the stock? Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended ...

Aug 10, 2023 · In the last 3 months, 7 analysts have offered 12-month price targets for Arcutis Biotherapeutics. The company has an average price target of $38.14 with a high of $57.00 and a low of $22.00.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) | 16,482 followers on LinkedIn. Bioscience, applied to the skin. | Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in ...Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 0.76 and has seen 2.92 million shares traded in the last trading session. The company, currently valued at $187.82M, closed the last trade at $1.99 per share which meant it gained $0.15 on the day or 8.15% during that session. ... The ARQT stock price is -806.53% off its 52 …ARQT Arcutis Biotherapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ)WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common …1 thg 2, 2021 ... Stock of Arcutis Biotherapeutics, a Westlake Village-based company developing dermatological treatments, shot up more than 30% on Feb.WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for ...Nov 28, 2023 · About Arcutis Biotherapeutics Inc. Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical ... WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common …Dec 2, 2023 · The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on December 1, 2023. WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock ...

Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Mar 6, 2023 · Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45. ARQT Arcutis Biotherapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ)Instagram:https://instagram. ishares canadabest kansas city banksdental insurance indiana no waiting periodmbs stock Arcutis Biotherapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.914. Following the earnings report the stock price went up 9.91%. Which hedge fund is a major shareholder of Arcutis Biotherapeutics? similar to bettermentpre ipo trading platform According to the issued ratings of 9 analysts in the last year, the consensus rating for Arcutis Biotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for ARQT. The average twelve-month price prediction for Arcutis Biotherapeutics is $33.78 with a high price target of $57.00 and a low price target of $6.00. etf that tracks oil price Aug 3, 2022 · In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and ... ARQT stock had a significant performance on November 3, 2023. According to data from CNN Money, eight analysts have offered 12-month price forecasts for Arcutis Biotherapeutics Inc, with a median target of $33.00. The high estimate for the stock price is $50.00, while the low estimate is $4.00.Arcutis Biotherapeutics Inc is down 6.97% from its previous closing price of $7.82. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $7.82 and $8.26. Currently, there are 61.43 million shares of Arcutis Biotherapeutics Inc stock available for purchase. Unfortunately, Arcutis Biotherapeutics Inc’s P/E ratio ...